{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-051179","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2025-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.232414+00:00","generated_at":"2026-05-23T21:07:35.420193+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Former CFO Marc Wilson transitions to consultant role through April 2026","bullets":["Wilson resigned as employee on April 1, 2025, and entered a consulting agreement through April 1, 2026, with a possible six-month extension.","He will receive $300 per hour for services plus reimbursement of reasonable out-of-pocket expenses.","Outstanding equity awards continue vesting during consulting period; accelerates upon termination without cause, death, disability, or change in control.","The agreement includes a general release of claims against the company."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-051179","json":"https://secwatch.observer/filing/0000950170-25-051179.json","markdown":"https://secwatch.observer/filing/0000950170-25-051179.md","text":"https://secwatch.observer/filing/0000950170-25-051179.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025051179/0000950170-25-051179-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025051179/crnx-20250401.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T21:07:35.420193+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"182d21074d","claim":"Marc Wilson resigned as other at Crinetics Pharmaceuticals, Inc..","evidence_excerpt":"pursuant to which Mr. Wilson resigned as an employee of the Company, effective April 1, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025051179/0000950170-25-051179-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}